Immunobrain Checkpoint, Inc is a pioneering company based in New York, NY, dedicated to transforming the understanding and treatment of neurodegeneration. They are redefining the treatment of neurological disorders by leveraging the body's own defense mechanisms and harnessing the power of the peripheral immune system to mitigate brain pathology.
With a focus on Alzheimer's disease, Immunobrain Checkpoint is currently investigating their lead program IBC-Ab002, a novel anti-PD-L1 antibody, in patients with early-stage Alzheimer's disease. They are building upon their unique understanding of how the peripheral immune system communicates with the brain, targeting it to benefit brain health.
Generated from the website